Lactococcus lactis JCM5805 activates anti-viral immunity and reduces symptoms of common cold and influenza in healthy adults in a randomized controlled trial

•This study was a randomized, double-blind controlled trial in 396 healthy subjects.•Heat-killed JCM5805 mitigated the incidence of common cold and influenza symptoms.•Heat-killed JCM5805 upregulated the expression levels of anti-viral genes.•Heat-killed JCM5805 upregulated the cell surface expressi...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of functional foods Vol. 24; pp. 492 - 500
Main Authors:	Shibata, Takeo, Kanayama, Masaya, Haida, Munetaka, Fujimoto, Shuhei, Oroguchi, Takashige, Sata, Kenji, Mita, Nobutaka, Kutsuzawa, Tomoko, Ikeuchi, Mayumi, Kondo, Mayu, Naito, Kimitoshi, Tsuda, Michio, Nishizaki, Yasuhiro, Ishii, Naoaki
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01-06-2016 Elsevier
Subjects:	Lactococcus lactis JCM5805 Plasmacytoid dendritic cells (pDCs) Randomized controlled double blind trial Viperin PP Lactococcus lactis JCM5805 JCM5805 LAB PBMC pDC IFN Plasmacytoid dendritic cells (pDCs) Viperin Randomized controlled double blind trial TLR HLA ISG NK
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•This study was a randomized, double-blind controlled trial in 396 healthy subjects.•Heat-killed JCM5805 mitigated the incidence of common cold and influenza symptoms.•Heat-killed JCM5805 upregulated the expression levels of anti-viral genes.•Heat-killed JCM5805 upregulated the cell surface expression of HLA-DR on pDCs. The effects of heat-killed Lactococcus lactis JCM5805 (JCM5805) on the pathogenesis of common cold and influenza were evaluated. A randomized, placebo-controlled, double-blinded study was conducted and 396 healthy subjects (placebo group n = 205, JCM5805 group n = 191) completed the intervention. Subjects consumed placebo capsules or JCM5805 capsules containing approximately 100 billion cells of heat-killed JCM5805 per day for 12 wk. Significantly fewer incident days were observed in the JCM5805 group than in the placebo group for the symptoms of sore throat (p < 0.05) and cough (p < 0.001). Cell surface expression of HLA-DR on plasmacytoid dendritic cells (pDC) and the expression of VIPERIN in peripheral blood mononuclear cells (PBMCs) were higher post-intervention compared to baseline in the JCM5805 group only (p < 0.05). The expression of IFNA in PBMCs was significantly higher in the JCM5805 group (p < 0.05). These data suggest that the intake of heat-killed JCM5805 stimulated pDC-related anti-viral immunity to mitigate the incidence of common cold and influenza symptoms.
ISSN:	1756-4646 2214-9414
DOI:	10.1016/j.jff.2016.03.035